Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sunny PharmtechROCO:6676 +0.41%58 3-Year ROIIC % is 176.73 as of Dec. 2025, which is 1389% above its 10-year median of 11.87. GuruFocus rates ROCO:6676 with a GF Score™ of 58/100 and a GF Value™ of NT$13.35 (Fairly Valued). The stock has 6 warning signs investors should review. Among 1,320 Biotechnology companies, Sunny Pharmtech ranks better than 83.48% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Sunny Pharmtech's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 176.73%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Sunny Pharmtech's 3-Year ROIIC % or its related term are showing as below:
ROCO:6676's 3-Year ROIIC % is ranked better than 83.48% of 1320
companies
in the Biotechnology industry
Industry Median: -4.82
vs ROCO:6676: 176.73
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Sunny Pharmtech 3-Year ROIIC % Related Terms
Sunny Pharmtech 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Sunny Pharmtech's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6676 vs VRTX, REGN, RVMD: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Sunny Pharmtech's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sunny Pharmtech 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sunny Pharmtech's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Sunny Pharmtech's 3-Year ROIIC % falls into.
Sunny Pharmtech's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -317.526 (Dec. 2025) - -187.62 (Dec. 2022) )
/
( 1358.006 (Dec. 2025) - 1431.511 (Dec. 2022) )
=
-129.906
/
-73.505
=
176.73%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Sunny Pharmtech (ROCO:6676) has a 3-Year ROIIC % of 176.73 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Sunny Pharmtech and its competitors. This is 1389% above median its historical median of 11.87. Over the past decade, Sunny Pharmtech's 3-Year ROIIC % has ranged from 1.42 to 259.33. According to the industry distribution chart, Sunny Pharmtech ranks #218 out of 1320 companies in the Biotechnology industry, placing it in the top 16.5%.
Is Sunny Pharmtech's 3-Year ROIIC % too high?
Sunny Pharmtech's current 3-Year ROIIC % of 176.73 is 1389% above median its 10-year median of 11.87. Over the past 10 years, this metric has ranged from a low of 1.42 to a high of 259.33. Based on the distribution chart, Sunny Pharmtech ranks #218 out of 1320 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Sunny Pharmtech has a GF Score™ of 58/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sunny Pharmtech's 3-Year ROIIC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sunny Pharmtech ranks #218 out of 1320 companies for 3-Year ROIIC %. This places Sunny Pharmtech in the top 17% of its industry — outperforming the majority of peers. Historically, Sunny Pharmtech's own 3-Year ROIIC % has ranged from 1.42 to 259.33 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Sunny Pharmtech and its competitors. Sunny Pharmtech's current 3-Year ROIIC % is 176.73, which is 1389% above median its own 10-year median of 11.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sunny Pharmtech stock overvalued right now?
Based on GuruFocus' analysis, Sunny Pharmtech (ROCO:6676) is currently considered Fairly Valued. The stock's GF Value™ is NT$13.35, compared to a current price of NT$12.35 — trading 7.5% below its estimated fair value. The current 3-Year ROIIC % is 176.73, which is 1389% above median its 10-year median of 11.87. Sunny Pharmtech's overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Sunny Pharmtech (ROCO:6676), the current 3-Year ROIIC % is 176.73 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sunny Pharmtech (ROCO:6676) Overvalued in 2026?
Based on GuruFocus' analysis, Sunny Pharmtech stock appears to be undervalued.
The current stock price of NT$12.35 is trading 7.5% below its estimated GF Value™ of NT$13.35.
GuruFocus considers Sunny Pharmtech to be Fairly Valued.
Key valuation signals for ROCO:6676:
3-Year ROIIC %: 176.73 (1389% above median its 10-year median of 11.87)
GF Value™: NT$13.35 vs. price of NT$12.35 (7.5% below fair value)
No single metric tells the full story. See the ROCO:6676 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sunny Pharmtech Inc is a specialty pharmaceutical company. It is now fully-integrated, doing research, development, and manufacturing on both API and finished-dose products, which includes orals, liquids, semi-solids, and parenterals.
58GF Score
Get the complete analysis for ROCO:6676
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6676 has been successfully added to your 
